文献速递细菌感染、耐药与抗菌药物新发突发、热带与寄生虫病

肯尼亚COVID-19前后大肠埃希菌和志贺菌的阿奇霉素耐药模式

Azithromycin Resistance Patterns in Escherichia coli and Shigella before and after COVID-19, Kenya.
PubMed 文献 · Emerg Infect Dis · 2024-01-01

该研究分析了肯尼亚2017-2019年(COVID-19前)1672份和2022-2023年(COVID-19后)1118份人类粪便样本中分离的116株大肠埃希菌和109株志贺菌,发现COVID-19后阿奇霉素耐药率从6.3%显著上升至40.4%(p=0.001),最常见的耐药基因为大环内酯类mph(A)基因。

要点

  • COVID-19后阿奇霉素耐药率从6.3%升至40.4%(p=0.001)。
  • 研究纳入116株大肠埃希菌和109株志贺菌分离株。
  • 最常见耐药基因为大环内酯类mph(A)基因。

核心结论

  • COVID-19后肯尼亚大肠埃希菌和志贺菌的阿奇霉素耐药率较COVID-19前显著上升,从6.3%增至40.4%(p=0.001)。
  • 本研究强调需要持续进行抗菌药物耐药监测。

研究设计与样本

  • 研究评估了来自肯尼亚COVID-19前(2017-2019年)1672份和COVID-19后(2022-2023年)1118份人类粪便样本的116株大肠埃希菌和109株志贺菌分离株的抗菌药物耐药趋势。
  • 部分分离株的表型耐药谱与全基因组测序获得的基因型耐药信息进行了比较。

主要发现

  • 阿奇霉素耐药率从COVID-19前的6.3%上升至COVID-19后的40.4%(p=0.001)。
  • 检测到的最常见耐药基因为大环内酯类mph(A)基因。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Escherichia coli and Shigella spp. are leading bacterial causes of acute diarrhea in sub-Saharan Africa and pose risks to global communities, travelers, and the US military. Increasing antimicrobial resistance (AMR) in those and other enteric pathogens creates treatment challenges for clinicians. Inappropriate use of antimicrobial drugs, such as azithromycin for viral respiratory infections, increased during the COVID-19 pandemic. We evaluated AMR trends of 116 E. coli and 109 Shigella spp. isolates obtained from 1,672 pre-COVID-19 (2017-2019) and 1,118 post-COVID-19 (2022-2023) human fecal samples from Kenya. Azithromycin resistance increased significantly from before to after COVID-19, from 6.3% to 40.4% (p = 0.001). Phenotypic AMR profiles from a subset of isolates were compared with genotypic AMR information derived from whole genome sequencing. The most common AMR gene detected was the macrolide mph(A) gene. This study highlights the need for continued AMR surveillance.

来源:Emerg Infect Dis,查看原文。版权归原作者所有。

引用

  1. Odundo EA, Kipkirui EC, Koech MC, et al. Azithromycin Resistance Patterns in Escherichia coli and Shigella before and after COVID-19, Kenya. Emerg Infect Dis. 2024. PMID: 39530877. doi:10.3201/eid3014.240374

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。